|

$100bn weight-loss drug race still in early stages

Novo Nordisk, Eli Lilly and most recently AstraZeneca have garnered significant attention with their advancements in weight-loss drugs. Polar Capital Global Healthcare’s James Douglas and Gareth Powell explore this potentially transformative moment in the global fight against obesity, and explain that while the impact on the healthcare industry is yet to be fully understood, these developments present a strong opportunity for healthcare investors across the market cap scale.